Company: CERO
Filing Date: 2025-02-06
Form Type: 8-K
Source: 0001213900-25-010731
Chunk: 0

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-06
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item
1.01 Entry into a Material Definitive Agreement.

On
February 5, 2025, CERo Therapeutics Holdings, Inc. (the “ Company”) announced the pricing of a reasonable best efforts public
offering (the “ Offering”), with participation from a member of the Company’s board of directors and a single institutional
investor, for the purchase and sale of (i) 2,551,020 shares of its common stock, par value $0.0001 per share (the “ Common Stock”)
or common stock equivalents in lieu thereof; and (ii) common warrants to purchase up to 2,551,020 shares of common stock (the “ Warrants”),
at a combined public offering price of $1.96 per share and Warrant. In connection with the Offering, on February 5, 2025, the Company
entered into a securities purchase agreement (the “ Purchase Agreement”) with the investors. The Purchase Agreement contains
customary representations, warranties and agreements of the Company and each investor and customary indemnification rights and obligations
of the parties.

The
Warrants have an exercise price of $1.96 per share, will be immediately exercisable upon stockholder approval and will have a term of
exercise equal to five years following date of the initial exercise date. The exercise price and number of shares of Common Stock issuable
upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting
the Common Stock and the exercise price.

In
connection with the Offering, on February 5, 2025, the Company entered into a placement agency agreement (the “ Placement Agency
Agreement”) with A. G. P./Alliance Global Partners (“ A. G. P.”), as the exclusive placement agent in connection with the
Offering (the “ Placement Agent”). Pursuant to a side letter between the Placement Agent and JonesTrading Institutional Services
LLC (“ Jones”), dated February 3, 2025, Jones agreed to be a financial advisor for the Offering. In connection with the services
provided by Jones, the Placement Agent and Jones agreed that the Placement Agent will receive an aggregate fee equal to 6% of the gross
proceeds received in the Offering and Jones will receive an aggregate fee equal to 3% of the gross proceeds received in the Offering.
In addition, the Company has agreed to reimburse the Placement Agent for its legal fees and expenses and other out